Skip to main content

Medical Disclaimer: This content is for informational and educational purposes only. The PHQ-9 and GAD-7 are screening tools, not diagnostic instruments. This comparison does not constitute medical advice. Please consult a qualified healthcare provider regarding any mental health concerns.

Clinically Validated ToolsEvidence-BasedFree Screening Tools

PHQ-9 vs. GAD-7: What's the Difference?

Use the PHQ-9 if you are screening for depression; use the GAD-7 if you are screening for anxiety. Because depression and anxiety co-occur in roughly 50% of cases, taking both tools is often the most clinically appropriate choice. This page is for anyone deciding which screening to take — or whether to take both. The comparison below covers scoring, clinical thresholds, and how the results relate to each other.

What is this?

A side-by-side comparison of the PHQ-9 (Patient Health Questionnaire-9) and GAD-7 (Generalized Anxiety Disorder-7), including what each tool measures, how they are scored, and when clinicians use each one.

Who needs it?

Anyone trying to decide whether to take the PHQ-9, the GAD-7, or both — and anyone who has received scores on both tools and wants to understand what they mean.

Bottom line

The PHQ-9 measures depressive symptoms; the GAD-7 measures anxiety symptoms. Both are validated, 5-minute screens. Many clinicians use both together because depression and anxiety frequently co-occur.

What is the PHQ-9?

The PHQ-9 (Patient Health Questionnaire-9) is a 9-item self-report screening tool developed to detect and measure the severity of major depressive disorder. It was developed by Kroenke, Spitzer, and Williams (2001) as part of the broader PHQ family of instruments and is now the most widely used depression screener in the world. The PHQ-9 is endorsed by the World Health Organization, CDC, and SAMHSA.

The nine questions map directly to the DSM-5 diagnostic criteria for major depressive disorder. Each question asks how often in the past two weeks you have been bothered by a symptom, rated on a 0–3 scale (Not at all / Several days / More than half the days / Nearly every day). The symptoms assessed are:

  • Little interest or pleasure in doing things
  • Feeling down, depressed, or hopeless
  • Sleep disturbance (too much or too little)
  • Feeling tired or having little energy
  • Poor appetite or overeating
  • Feeling bad about yourself or that you are a failure
  • Trouble concentrating on things
  • Moving or speaking more slowly — or being fidgety/restless
  • Thoughts that you would be better off dead or of hurting yourself

Scores range from 0 to 27. The commonly cited clinical cutoff for major depression is a score of 10 or higher, though the full severity range is: 0–4 minimal, 5–9 mild, 10–14 moderate, 15–19 moderately severe, 20–27 severe. Question 9 (thoughts of self-harm) is flagged separately regardless of overall score.

What is the GAD-7?

The GAD-7 (Generalized Anxiety Disorder-7) is a 7-item self-report screening tool designed to detect generalized anxiety disorder (GAD) and measure anxiety symptom severity. It was developed by Spitzer, Kroenke, Williams, and Löwe (2006) and validated in primary care settings with strong sensitivity (89%) and specificity (82%). Like the PHQ-9, it uses a 0–3 frequency scale over the past two weeks.

The seven items assess core GAD symptoms based on DSM criteria:

  • Feeling nervous, anxious, or on edge
  • Not being able to stop or control worrying
  • Worrying too much about different things
  • Trouble relaxing
  • Being so restless that it is hard to sit still
  • Becoming easily annoyed or irritable
  • Feeling afraid as if something awful might happen

Scores range from 0 to 21. Severity levels: 0–4 minimal, 5–9 mild, 10–14 moderate, 15–21 severe. A score of 10 or higher is the standard clinical cutoff for probable generalized anxiety disorder, matching the PHQ-9's moderate threshold for comparability when both are co-administered.

How are the PHQ-9 and GAD-7 different?

Despite their structural similarities — both use a 0–3 frequency scale and are anchored to the past two weeks — the PHQ-9 and GAD-7 target fundamentally different constructs and symptom domains.

FeaturePHQ-9GAD-7
Primary targetMajor depressive disorderGeneralized anxiety disorder
Number of items9 items7 items
Score range0–270–21
Clinical cutoff≥10 (moderate+)≥10 (moderate+)
Administration time~2–3 minutes~1–2 minutes
Sensitivity / Specificity88% / 88% for MDD89% / 82% for GAD
Includes self-harm itemYes (item 9)No
DSM criteria mappedDSM-5 MDD criteriaDSM-5 GAD criteria

One structural difference worth noting: the PHQ-9 includes question 9, which directly asks about thoughts of self-harm or suicide. This item is flagged separately by clinicians regardless of total score. The GAD-7 does not include a suicidality item — a clinician administering only the GAD-7 would use a separate suicide risk assessment if indicated.

Can you take both the PHQ-9 and GAD-7 at the same time?

Yes — and this is exactly how they are most often used in clinical practice. Many primary care offices, behavioral health programs, and telehealth platforms include both tools on intake forms because depression and anxiety are highly comorbid. The combined PHQ-9 + GAD-7 administration takes under 5 minutes and provides a comprehensive baseline across both symptom domains.

The PHQ Screeners website (the official source maintained by Pfizer) offers both tools as a combined packet. The PHQ-4, a 4-item ultra-brief screener, draws its 4 items directly from the first 2 questions of each tool for the fastest possible triage — positive results on the PHQ-4 are followed up with the full PHQ-9 and/or GAD-7.

Taking both tools together is particularly valuable because overlapping symptoms — sleep disruption, difficulty concentrating, fatigue, and irritability — appear in both depression and anxiety. The full PHQ-9 and GAD-7 allow a trained clinician to differentiate the pattern and weight of symptoms more accurately than either tool alone.

Which tool should I take — PHQ-9 or GAD-7?

The short answer: if you are uncertain, take both. They take under 5 minutes combined. However, your symptom pattern can help guide the choice:

Use the PHQ-9 if your primary concern is depression

Low mood or sadness most days, loss of interest in activities you used to enjoy, fatigue, feelings of worthlessness or hopelessness, changes in sleep or appetite, or thoughts of not wanting to be alive. These symptoms align more closely with the PHQ-9's depression construct.

Use the GAD-7 if your primary concern is anxiety

Persistent excessive worry that you cannot control, feeling on edge or keyed up, physical tension, restlessness, irritability, or fear that something bad will happen. These symptoms align more closely with the GAD-7's anxiety construct.

Take both if you are unsure or have mixed symptoms

Sleep problems, difficulty concentrating, fatigue, and irritability overlap both constructs. If you are not sure whether what you are feeling is depression, anxiety, or both, taking both tools gives you a more complete picture to discuss with a healthcare provider.

No screening tool can replace clinical judgment. These results are most useful as a structured starting point for a conversation with a qualified mental health professional or primary care provider.

What do the scores mean on each tool?

Both tools use the same 0–3 frequency scale for individual items and share a ≥10 clinical cutoff for the moderate severity band, but the total score ranges differ (PHQ-9: 0–27; GAD-7: 0–21) because of the different number of items.

PHQ-9 Severity Levels

  • 0–4: Minimal depression
  • 5–9: Mild depression
  • 10–14: Moderate depression
  • 15–19: Moderately severe depression
  • 20–27: Severe depression

Clinical cutoff: ≥10 warrants evaluation

GAD-7 Severity Levels

  • 0–4: Minimal anxiety
  • 5–9: Mild anxiety
  • 10–14: Moderate anxiety
  • 15–21: Severe anxiety

Clinical cutoff: ≥10 warrants evaluation

Scores in the mild range (PHQ-9: 5–9; GAD-7: 5–9) may warrant watchful waiting and lifestyle interventions. Scores in the moderate range or above warrant clinical evaluation. All results should be interpreted alongside other clinical information — a high score alone does not constitute a diagnosis.

When do clinicians use the PHQ-9 and GAD-7 together versus separately?

Clinical guidelines from organizations including the National Institute of Mental Health (NIMH) and the U.S. Preventive Services Task Force (USPSTF) support routine screening for both depression and anxiety in primary care. The USPSTF recommends screening for depression in adults and anxiety in adults 64 and younger.

In practice, clinicians typically use both tools together during initial intake, periodic monitoring (e.g., every 4–8 weeks during treatment), and at treatment transitions. Using both allows clinicians to track whether interventions are improving depression, anxiety, or both — and to adjust treatment accordingly.

In settings where time is extremely limited, the PHQ-4 serves as a 2-minute triage tool. Any positive PHQ-4 result is then followed up with the full PHQ-9 and/or GAD-7 to establish a more precise symptom profile before clinical decision-making.

Sources & Further Reading

  • Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613.
  • Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder. Arch Intern Med. 2006;166(10):1092–1097.
  • PHQscreeners.com — Official PHQ and GAD instruments, scoring, and instructions.
  • SAMHSA.gov — National Helpline and behavioral health screening resources.
  • U.S. Preventive Services Task Force. Screening for Anxiety in Adults (2023). uspreventiveservicestaskforce.org

Frequently Asked Questions

What is the difference between depression and anxiety?

Depression and anxiety are distinct but related conditions. Depression is primarily characterized by persistent low mood, loss of interest or pleasure, fatigue, and feelings of worthlessness or hopelessness. Anxiety is characterized by excessive worry, fear, nervousness, and physical symptoms like muscle tension, racing heart, and restlessness. Both can disrupt sleep, concentration, and daily functioning. Depression and anxiety frequently co-occur — estimates suggest 45–60% of people with major depression also meet criteria for an anxiety disorder.

Can depression and anxiety occur together?

Yes. Comorbid depression and anxiety is common. Research published in journals including JAMA Psychiatry and the Journal of Affective Disorders consistently shows that 45–60% of people with major depressive disorder also have a diagnosable anxiety disorder. This is one reason clinicians often administer both the PHQ-9 and GAD-7 together — to get a fuller picture of a patient's mental health status in a single brief administration.

How long does each screening take?

Both tools are brief. The PHQ-9 has 9 items and typically takes 2–3 minutes to complete. The GAD-7 has 7 items and typically takes 1–2 minutes. Together, they can be administered in under 5 minutes, which is why many primary care practices routinely include both on intake paperwork or electronic health record check-ins.

Are the PHQ-9 and GAD-7 clinically validated tools?

Yes. Both tools have undergone extensive psychometric validation. The PHQ-9 was developed and validated by Kroenke and Spitzer (2001) in primary care populations with strong sensitivity (88%) and specificity (88%) for major depressive disorder. The GAD-7 was validated by Spitzer, Kroenke, Williams, and Löwe (2006) with sensitivity of 89% and specificity of 82% for generalized anxiety disorder. Both are endorsed by the World Health Organization, SAMHSA, and major professional medical associations.

What should I do if I score high on both the PHQ-9 and GAD-7?

A high score on both tools — for example, PHQ-9 ≥10 and GAD-7 ≥10 — suggests significant depressive and anxiety symptoms are both present. This is common and does not mean something is 'more wrong' with you; comorbidity is the norm rather than the exception. You should speak with a healthcare provider as soon as possible. A clinician can conduct a full evaluation, determine which symptoms are primary, and develop a treatment plan. These screening results are a starting point for conversation, not a diagnosis.

Do healthcare providers typically use the PHQ-9 and GAD-7 together?

Yes. Using both tools together is standard practice in primary care, behavioral health integration programs, and telehealth settings. The combined PHQ-9/GAD-7 protocol provides a rapid dual-screen for depression and anxiety in approximately 5 minutes. The PHQ-4 is a 4-item ultra-brief screen that combines the first 2 items of each tool for the fastest possible triage, with PHQ-9 and GAD-7 used for deeper assessment when PHQ-4 is positive.

Can I use the PHQ-9 or GAD-7 without a doctor?

You can take either screening tool on your own — both are in the public domain and freely available. Self-screening can help you recognize patterns in your symptoms and decide whether to seek professional evaluation. However, these tools are not diagnostic instruments. A score above a clinical threshold means your symptoms warrant professional evaluation, not that you have been diagnosed with a specific condition. Always discuss results with a qualified healthcare provider.

What do the different severity levels mean on each tool?

PHQ-9 severity levels: 0–4 minimal depression, 5–9 mild, 10–14 moderate, 15–19 moderately severe, 20–27 severe. GAD-7 severity levels: 0–4 minimal anxiety, 5–9 mild, 10–14 moderate, 15–21 severe. On both tools, scores in the moderate range (PHQ-9 ≥10; GAD-7 ≥10) are the commonly cited clinical cutoffs for warranting further evaluation. These cutoffs were established in validation studies but should always be interpreted in clinical context by a trained provider.

Take the Screening Tools

Reviewed by Jason Ramirez, CADC-II

Certified Drug and Alcohol Counselor (CADC-II) · 11 years of clinical experience

Published: Updated: